Archives of Dermatological Research

, Volume 310, Issue 9, pp 701–710 | Cite as

Achieving international consensus on the assessment of psoriatic arthritis in psoriasis clinical trials: an International Dermatology Outcome Measures (IDEOM) initiative

  • Lourdes Maria Perez-Chada
  • Jeffrey M. Cohen
  • Alice Bendix Gottlieb
  • Kristina Callis Duffin
  • Amit Garg
  • John Latella
  • April Wang Armstrong
  • Alexis Ogdie
  • Joseph Frank MerolaEmail author
Original Paper


Psoriatic arthritis (PsA) is rarely assessed in psoriasis randomized controlled trials (RCT); thus, the effect of psoriasis therapy on PsA is unknown. The International Dermatology Outcome Measures (IDEOM) has included “PsA Symptoms” as part of the core domains to be measured in psoriasis RCT. This study aimed to achieve consensus about screening for PsA and how to measure for “PsA Symptoms” in psoriasis RCT. At the IDEOM 2017 Annual Meeting, stakeholders voted on the role of PsA screening in psoriasis RCT. To select measures for “PsA Symptoms”, we adapted the Consensus-Based Standards for the Selection of Health Measurement Instruments (COSMIN) guidelines. Three potential measures were selected. At the meeting, stakeholders voted on the validity, feasibility, and responsiveness of these measures. Of the 47 stakeholders, 93% voted that all psoriasis trial participants should be screened for PsA. “PsA Symptoms” measures included Patient Global (PG)-arthritis, Routine Assessment Patient Index Data (RAPID)-3, and Psoriatic Arthritis Impact of Disease (PsAID)-9. During the voting, more than 50% of the voters agreed that RAPID3 and PsAID9 were good measures for PsA Symptoms, able to capture all its essential elements. PsAID9 was considered the most feasible instrument, followed by RAPID3 and PG-arthritis, respectively. Finally, most participants agreed that RAPID3 and PsAID9 were responsive measures. Most study participants voted that all subjects in a psoriasis clinical trial should be screened for PsA. RAPID3 and PsAID9 outperformed PG-arthritis in measuring PsA Symptoms. This will be followed by a Delphi survey involving a larger stakeholder group.


Psoriatic arthritis Patient-reported outcome measures Clinical trials Psychometric Screening 



We thank Dr. Philip Mease for his collaboration in the design of the Delphi Survey during the 2018 GRAPPA adjacent to the AAD Meeting in San Diego, CA, USA.


This study was funded by the International Dermatology Outcome Measures group.

Compliance with ethical standards

Conflict of interest

Dr. Gottlieb is an advisor/consultant for Janssen Inc.; Celgene Corp., Bristol Myers Squibb Co., Beiersdorf, Inc., Abbvie, UCB, Novartis, Incyte, Pfizer, Lilly, Xenoport, Development Crescendo Bioscience, Aclaris, Amicus, Reddy Labs, Valeant, Dermira, Allergan, CSL Behring, Merck, Sun Pharmaceutical Industries. Also, she received research/educational grants from Janssen, Incyte. Dr. Duffin has been a consultant and/or investigator for Amgen, Janssen, Lilly, Novartis, Celgene, Pfizer; Bristol-Myers Squibb Co. Dr. Garg served on the advisory board of Abbvie, Janssen, and Pfizer receiving honoraria. Also, he received research/educational grants from AbbVie and Merck. Dr. Armstrong has served as investigator, advisor and/or consultant to AbbVie, Janssen, Novartis, Lilly, Regeneron, Sanofi, Science 37, Modernizing Medicine, and Valeant. Dr. Merola has served as an advisor/consultant for Biogen IDEC, AbbVie, Amgen, Eli Lilly, Novartis, Pfizer, Janssen, UCB, Kiniksa, Momenta and Mallinckrodt. He has been a speaker for AbbVie and Eli Lilly, and an investigator for Biogen IDEC, Amgen, Pfizer and Boehringer Ingelheim. Dr. Ogdie served as a consultant for Bristol-Myers Squibb, Lilly, Novartis, Pfizer, and Takeda and has received grant funding to the University of Pennsylvania from Pfizer (co-investigator) and Novartis. John Latella has served as Patient Consultant for Boehringer Ingelheim, and Patient Advocate for GfK. Dr. Perez-Chada has received research funding from “RADLA Scholarship 2010”. The other authors have no disclosures.

Research involving human participants and/or animals

Evaluation by an ethical board was deemed exempt given the nature of a consensus meeting. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Process to obtain informed consent was deemed exempt given the nature of a consensus meeting.

Supplementary material

403_2018_1855_MOESM1_ESM.pdf (98 kb)
Online Resource 1: Table comparing the characteristics of different screening tools (PDF 98 KB)
403_2018_1855_MOESM2_ESM.pdf (85 kb)
Online Resource 2: Table presenting the eligibility criteria to select “PsA Symptoms” measures (PDF 85 KB)
403_2018_1855_MOESM3_ESM.pdf (99 kb)
Online Resource 3: Pubmed search strategy to identify articles reporting the psychometric properties of the PG-arthritis VAS, PG-arthritis NRS, RAPID3, PsAID9 and PsAID12 (PDF 99 KB)
403_2018_1855_MOESM4_ESM.pdf (89 kb)
Table presenting the definition of psychometric terms (PDF 89 KB)
403_2018_1855_MOESM5_ESM.pdf (243 kb)
Overview and summary of the psychometric properties of the PG-arthritis VAS, PG-arthritis NRS, RAPID3, PsAID9 and PsAID12 (PDF 242 KB)


  1. 1.
    Boehncke WH, Menter A (2013) Burden of disease: psoriasis and psoriatic arthritis. Am J Clin Dermatol 14:377–388. CrossRefPubMedGoogle Scholar
  2. 2.
    Callis Duffin K, Gottlieb AB, Merola JF, Latella J, Garg A, Armstrong AW (2017) Defining outcome measures for psoriasis: the IDEOM Report from the GRAPPA 2016 annual meeting. J Rheumatol 44:701–702. CrossRefPubMedGoogle Scholar
  3. 3.
    Cauli A, Gladman DD, Mathieu A, Olivieri I, Porru G, Tak PP, Sardu C, Ujfalussy I, Scarpa R, Marchesoni A (2011) Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. J Rheumatol 38:898–903CrossRefGoogle Scholar
  4. 4.
    Cauli A, Gladman DD, Mathieu A, Olivieri I, Porru G, Tak PP, Sardu C, Ujfalussy I, Scarpa R, Marchesoni A, Taylor WJ, Spadaro A, Fernandez-Sueiro JL, Salvarani C, Kalden JR, Lubrano E, Carneiro S, Desiati F, Flynn JA, D’Angelo S, Vacca A, AW VANK, Catanoso MG, Gruenke M, Peluso R, Parsons WJ, Ferrara N, Contu P, Helliwell PS, Mease PJ (2011) Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. J Rheumatol 38:898–903. CrossRefPubMedGoogle Scholar
  5. 5.
    Coates L (2015) Outcome measures in psoriatic arthritis. Rheum Dis Clin N Am 41:699–710. CrossRefGoogle Scholar
  6. 6.
    Coates L, Aslam T, Al Balushi F, Burden A, Burden-The E, Caperon A, Cerio R, Chattopadhyay C, Chinoy H, Goodfield M (2013) Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study). Br J Dermatol 168:802–807CrossRefGoogle Scholar
  7. 7.
    Coates L, Tillett W, Pincus T, Kavanaugh A, Helliwell P (2016) THU0419 Rapid3 performs well identifying treatment effect in the tight control of psoriatic arthritis study. BMJ Publishing Group Ltd, LondonGoogle Scholar
  8. 8.
    Coates LC, Tillett W, Pincus T, Kavanaugh A, Helliwell PS (2016) RAPID3 near remission shows good agreement with minimal disease activity criteria in psoriatic arthritis [abstract]. Arthritis Rheumatol 68(suppl 10)Google Scholar
  9. 9.
    Coates LC, Walsh J, Haroon M, FitzGerald O, Aslam T, Al Balushi F, Burden A, Burden-Teh E, Caperon AR, Cerio R (2014) Development and testing of new candidate psoriatic arthritis screening questionnaires combining optimal questions from existing tools. Arthritis Care Res 66:1410–1416CrossRefGoogle Scholar
  10. 10.
    Coster WJ (2013) Making the best match: selecting outcome measures for clinical trials and outcome studies. Am J Occup Ther 67:162–170. CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    de Wit M, Kvien T, Gossec L (2015) Patient participation as an integral part of patient-reported outcomes development ensures the representation of the patient voice: a case study from the field of rheumatology. RMD Open 1:e000129CrossRefGoogle Scholar
  12. 12.
    de Wit MP, Kvien TK, Gossec L (2015) Patient participation as an integral part of patient-reported outcomes development ensures the representation of the patient voice: a case study from the field of rheumatology. RMD Open 1:e000129. CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Di Carlo M, Becciolini A, Lato V, Crotti C, Favalli EG, Salaffi F (2017) The 12-item Psoriatic Arthritis Impact of Disease Questionnaire: construct validity, reliability, and interpretability in a clinical setting. J Rheumatol 44:279–285. CrossRefPubMedGoogle Scholar
  14. 14.
    Eder L, Thavaneswaran A, Chandran V, Cook R, Gladman DD (2015) Factors explaining the discrepancy between physician and patient global assessment of joint and skin disease activity in psoriatic arthritis patients. Arthritis Care Res 67:264–272. CrossRefGoogle Scholar
  15. 15.
    Elman SA, Merola JF, Armstrong AW, Duffin KC, Latella J, Garg A, Gottlieb AB (2017) The International Dermatology Outcome Measures (IDEOM) Initiative: a review and update. J Drugs Dermatol 16:119–124PubMedGoogle Scholar
  16. 16.
    Favier G, Gladman DD, Merola JF, Armstrong AW, Boehncke WH, Helliwell PS (2017) Benchmarking care in psoriatic arthritis—the QUANTUM Report: a report from the GRAPPA 2016 annual meeting. J Rheumatol 44:674–678. CrossRefPubMedGoogle Scholar
  17. 17.
    Gossec L, de Wit M, Kiltz U, Braun J, Kalyoncu U, Scrivo R, Maccarone M, Carton L, Otsa K, Sooaar I, Heiberg T, Bertheussen H, Canete JD, Sanchez Lombarte A, Balanescu A, Dinte A, de Vlam K, Smolen JS, Stamm T, Niedermayer D, Bekes G, Veale D, Helliwell P, Parkinson A, Luger T, Kvien TK (2014) A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis 73:1012–1019. CrossRefPubMedGoogle Scholar
  18. 18.
    Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, Van Voorhees AS, Elmets CA, Leonardi CL, Beutner KR, Bhushan R, Menter A (2008) Guidelines of care for the management of psoriasis and psoriatic arthritis: Sect. 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 58:851–864. CrossRefPubMedGoogle Scholar
  19. 19.
    Haroon M, Kirby B, FitzGerald O (2013) High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann Rheum Dis 72:736–740. CrossRefPubMedGoogle Scholar
  20. 20.
    Helliwell P, Coates L, Chandran V, Gladman D, de Wit M, FitzGerald O, Kavanaugh A, Strand V, Mease PJ, Boehncke WH, Langley RG, Lubrano E, Maccarone M, Schulze-Koops H, Miceli-Richard C, Queiro R (2014) Qualifying unmet needs and improving standards of care in psoriatic arthritis. Arthritis Care Res 66:1759–1766. CrossRefGoogle Scholar
  21. 21.
    Hojgaard P, Klokker L, Orbai AM, Holmsted K, Bartels EM, Leung YY, Goel N, de Wit M, Gladman DD, Mease P, Dreyer L, Kristensen LE, FitzGerald O, Tillett W, Gossec L, Helliwell P, Strand V, Ogdie A, Terwee CB, Christensen R (2017) A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: a GRAPPA-OMERACT initiative. Semin Arthritis Rheum. CrossRefPubMedGoogle Scholar
  22. 22.
    Husni ME, Meyer KH, Cohen DS, Mody E, Qureshi AA (2007) The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool. J Am Acad Dermatol 57:581–587CrossRefGoogle Scholar
  23. 23.
    Ibrahim G, Buch M, Lawson C, Waxman R, Helliwell P (2009) Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire. Clin Exp Rheumatol 27:469PubMedGoogle Scholar
  24. 24.
    Leung YY, Ho KW, Zhu TY, Tam LS, Kun EW, Li EK (2012) Construct validity of the modified numeric rating scale of patient global assessment in psoriatic arthritis. J Rheumatol 39:844–848. CrossRefPubMedGoogle Scholar
  25. 25.
    Mease PJ (2011) Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res 63(Suppl 11):S64–S85. CrossRefGoogle Scholar
  26. 26.
    Michelsen B, Fiane R, Diamantopoulos AP, Soldal DM, Hansen IJ, Sokka T, Kavanaugh A, Haugeberg G (2015) A comparison of disease burden in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. PloS One 10:e0123582. CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Mokkink LB, de Vet HCW, Prinsen CAC, Patrick DL, Alonso J, Bouter LM, Terwee CB (2017) COSMIN risk of bias checklist for systematic reviews of patient-reported outcome measures. Qual Life Res. CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Mokkink LB, Prinsen CA, Bouter LM, Vet HC, Terwee CB (2016) The COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) and how to select an outcome measurement instrument. Braz J Phys Ther 20:105–113. CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Mokkink LB, Terwee CB, Knol DL, Stratford PW, Alonso J, Patrick DL, Bouter LM, de Vet HC (2010) The COSMIN checklist for evaluating the methodological quality of studies on measurement properties: a clarification of its content. BMC Med Res Methodol 10:22. CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Ogdie A, Weiss P (2015) The epidemiology of psoriatic arthritis. Rheum Dis Clin N Am 41:545–568. CrossRefGoogle Scholar
  31. 31.
    Orbai AM, de Wit M, Mease P, Shea JA, Gossec L, Leung YY, Tillett W, Elmamoun M, Callis Duffin K, Campbell W, Christensen R, Coates L, Dures E, Eder L, FitzGerald O, Gladman D, Goel N, Grieb SD, Hewlett S, Hoejgaard P, Kalyoncu U, Lindsay C, McHugh N, Shea B, Steinkoenig I, Strand V, Ogdie A (2017) International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. Ann Rheum Dis 76:673–680. CrossRefPubMedGoogle Scholar
  32. 32.
    Orbai AM, Ogdie A (2016) Patient-reported outcomes in psoriatic arthritis. Rheum Dis Clin N Am 42:265–283. CrossRefGoogle Scholar
  33. 33.
    Perez-Chada LM, Singh S, Callis-Duffin K, Garg A, Gottlieb AB, Latella J, Armstrong AW, Merola JF (2017) International Dermatology Outcome Measures (IDEOM) Group 2016 New York Meeting: meeting summary and data from the Psoriasis Working Group. J Drugs Dermatol 16:770–777PubMedGoogle Scholar
  34. 34.
    Porter ME, Larsson S, Lee TH (2016) Standardizing patient outcomes measurement. N Engl J Med 374:504–506. CrossRefPubMedGoogle Scholar
  35. 35.
    Prinsen CA, Vohra S, Rose MR, Boers M, Tugwell P, Clarke M, Williamson PR, Terwee CB (2016) How to select outcome measurement instruments for outcomes included in a “Core Outcome Set”—a practical guideline. Trials 17:449CrossRefGoogle Scholar
  36. 36.
    Salaffi F, Di Carlo M, Carotti M, Farah S, Gutierrez M (2016) The Psoriatic Arthritis Impact of Disease 12-item questionnaire: equivalence, reliability, validity, and feasibility of the touch-screen administration versus the paper-and-pencil version. Ther Clin Risk Manag 12:631–642. CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Talli S, Etcheto A, Fautrel B, Balanescu A, Braun J, Canete JD, de Vlam K, de Wit M, Heiberg T, Helliwell P, Kalyoncu U, Kiltz U, Maccarone M, Niedermayer D, Otsa K, Scrivo R, Smolen JS, Stamm T, Veale DJ, Kvien TK, Gossec L (2016) Patient global assessment in psoriatic arthritis - what does it mean? An analysis of 223 patients from the Psoriatic arthritis impact of disease (PsAID) study. Joint Bone Spine 83:335–340. CrossRefPubMedGoogle Scholar
  38. 38.
    Terwee CB, Mokkink LB, Knol DL, Ostelo RW, Bouter LM, de Vet HC (2012) Rating the methodological quality in systematic reviews of studies on measurement properties: a scoring system for the COSMIN checklist. Qual Life Res 21:651–657. CrossRefPubMedGoogle Scholar
  39. 39.
    Tom BD, Chandran V, Farewell VT, Rosen CF, Gladman DD (2015) Validation of the Toronto psoriatic arthritis screen version 2 (ToPAS 2). J Rheumatol 42:841–846CrossRefGoogle Scholar
  40. 40.
    Vakil-Gilani K, Dinno A, Garg N, Deodhar AA (2015) Routine Assessment of Patient Index Data 3 Score (rapid3) and Psoriasis Quality of Life (pqol-12) Assess Different Domains in Psoriasis (pso) and Psoriatic Arthritis (psa) Patients. Arthritis Rheumatol 67:897–898Google Scholar
  41. 41.
    Yazici Y, Bergman M, Pincus T (2008) Time to score quantitative rheumatoid arthritis measures: 28-Joint Count, Disease Activity Score, Health Assessment Questionnaire (HAQ), Multidimensional HAQ (MDHAQ), and Routine Assessment of Patient Index Data (RAPID) scores. J Rheumatol 35:603–609PubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Dermatology, Brigham and Women’s HospitalHarvard Medical SchoolBostonUSA
  2. 2.The Ronald O. Perelman Department of DermatologyNew York University School of MedicineNew YorkUSA
  3. 3.Department of DermatologyNew York Medical College at Metropolitan HospitalNew YorkUSA
  4. 4.Department of DermatologyUniversity of UtahSalt Lake CityUSA
  5. 5.Department of DermatologyHofstra Northwell School of MedicineNew Hyde ParkUSA
  6. 6.International Dermatology Outcome Measures (IDEOM)WindsorUSA
  7. 7.Department of DermatologyUniversity of Southern California Keck School of MedicineLos AngelesUSA
  8. 8.Division of Rheumatology and Center for Clinical Epidemiology and Biostatistics, Perelman School of MedicineUniversity of PennsylvaniaPhiladelphiaUSA
  9. 9.Division of Rheumatology, Department of MedicineBrigham and Women’s HospitalBostonUSA

Personalised recommendations